Bluejay Diagnostics (BJDX) Gross Margin (2022)
Bluejay Diagnostics recorded quarterly Gross Margin of 19.64% in Q2 2022.
Bluejay Diagnostics' Gross Margin history runs 1 years deep, the most recent figure standing at 19.64% for Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 63.83% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 78.01% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 45.22% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 62.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 38.53% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 43.89% |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 19.64% |